ECTRIMS 2018 Conference Review

In this review: 

Predicting conversion to MS in patients with CIS
Use of the review of systems questionnaire in a MS referral clinic
Late clinical activity in patients with long-standing non-active MS
Risk stratification decreases the incidence of natalizumab-associated PML
Extended interval dosing of natalizumab
Ozanimod is effective for early and advanced relapsing MS
Autologous stem cell transplantation in MS
Oral drugs vs platform injectables as first-line DMT
Treatment escalation or switch to another moderately effective therapy?
Relationship between ORS and patient-reported outcomes on the SF-36

Please login below to download this issue (PDF)